Purpose Tau accumulation is a core pathologic change in various neurodegenerative diseases including Alzheimer's disease and frontotemporal lobar degeneration-tau. Recently, tau positron emission tomography tracers such as [ In the present study, we performed a head to head comparison of these two tracers in Alzheimer's disease and frontotemporal dementia cases and aimed to investigate which tracers are better suited to image tau in these disorders.
F] THK5351 have been developed to detect tau deposition in vivo. In the present study, we performed a head to head comparison of these two tracers in Alzheimer's disease and frontotemporal dementia cases and aimed to investigate which tracers are better suited to image tau in these disorders.
Methods A cross-sectional study was conducted using a hospital-based sample at a tertiary referral center. We recruited eight participants (two Alzheimer 's disease, four frontotemporal dementia and two normal controls) who underwent magnetic resonance image, amyloid positron emission tomography with [ 18 F]-Florbetaben and tau positron emission tomography with both THK5351 and AV-1451. To measure regional AV1451 and THK5351 uptakes, we used the standardized uptake value ratios by dividing mean activity in target volume of interest by mean activity in the cerebellar hemispheric gray matter.
Introduction
Alzheimer's disease (AD) is characterized by extracellular neuritic plaques composed of aggregated amyloid-beta (Aβ) and intracellular neurofibrillary tangles (NFT) consisting of paired helical filaments (PHF) of hyperphosphorylated aggregated tau [1] . Frontotemporal dementia represents a family of disorders associated with either underlying tau aggregates (FTLD-tau) including pathological subtypes Pick's disease, corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) or TAR DNA-binding protein of 43 kDa (TDP-43) aggregates. The behavioral variant of FTD (bvFTD) is associated with underlying FTLD-tau in~50% of patients. The language variant non-fluent variant primary progressive aphasia (nfvPPA) is usually (~70%) associated with underlying tauopathy, while semantic variant PPA (svPPA) is associated with FTLD-TDP in the vast majority (~80% of cases) [2] [3] [4] . In FTLD-tau, tau aggregates appear ultrastructurally as straight, randomly coiled or twisted filaments, rather than PHF [5] . Also, FTLD-tau has three repeats (3R) or four repeats (4R): 3R in Pick's disease and 4R in CBD and PSP [6] .
Along with rapid development of molecular imaging, a number of promising tau positron emission tomography (PET) tracers including [ 18 F ] THK5351 (THK5351) and [ 18 F ] AV-1451(AV-1451) have been developed. THK5351 has a higher tau affinity than amyloid β [7] and shows increased cortical uptake in AD and FTD syndromes [8, 9] . AV-1451 has more than 25-fold selectivity for tau over amyloid β [10] . AV-1451 also showed correlation with Braak's NFT stage [11, 12] , cognitive status, and cortical atrophy [13] . In previous studies, both THK5351 and AV-1451 showed off-target binding, thought to be unrelated to tau, in the midbrain and basal ganglia [14, 15] . More recent pathology studies raised the possibility that THK5351 and AV-1451 have distinct characteristics. That is, AV-1451 binds to strongly PHF-tau observed in AD or FTD patients with specific mutations in the MAPT gene, but binding to straight form tau observed in most of FTLD-tau is weak to absent [16, 17] . However, THK-5351, a quinolone-derivative agent, might bind to monoamine oxidase B (MAO-B) [18] . Specifically, a significant proportion of THK signal may reflect normal MAO-B activity in basal ganglia or MAO-B expression from reactive astrocytes due to neuroinflammation states [19] .
To our knowledge, there have been no head to head comparison studies imaging the same patients with both THK5351 and AV-1451. Given each tracer has distinct characteristics, comparing different tracers in the same subjects might be helpful to select the more suitable tracer in AD and FTD with different tau aggregates. Also, direct comparison of off-target binding between THK5351 and AV-1451 is important, particularly when the goal is to image subcortical tau deposition in certain disorders.
In the present study, we performed a head to head comparison of THK5351 and AV-1451 in AD, FTD and normal controls (NC). We determined whether the degree and distribution of THK5351 and AV-1451 cortical uptake differed between AD and FTD. We also examined whether THK5351 and AV-1451 tracers exhibited different degrees and distribution of off-target binding. [21] and FTD dementia syndrome [22, 23] . Cases 1 and 2 were clinically diagnosed with early onset AD and logopenic variant primary progressive aphasia (lvPPA), a language-variant of AD [23] . Cases 3-6 were clinically diagnosed with FTD syndromes, including svPPA, nfvPPA and bvFTD (N = 2) [22] [23] [24] . Cases 7 and 8 were CN defined by detailed neuropsychological and neuroimaging studies. None of the participants had large infarction, brain tumor, or other brain lesions.
Materials and methods

Participants
This study was approved by the institutional review board of Samsung Medical Center, and written informed consent was obtained from all participants. F ] THK5351 PET images were acquired for 20 min, starting at 50 min after the IV bolus injection of 185 ± 18.5 MBq of 18F-THK5351. Before the PET scan, we applied a head holder to minimize head motion and also acquired brain CT images for attenuation correction. Finally, using the ordered-subsets expectation maximization algorithm (iteration = 4 and subset = 16), three dimensional (3D) PET images were reconstructed in a 128 × 128 × 47 matrix with a 2.0 × 2.0 × 3.27 mm voxel size. PET images were assessed visually by in-person-trained experts. Specifically, interpreters checked a regional cortical tracer uptake in the frontal, lateral temporal, posterior cingulate/precuneus, and parietal regions. Presence of increased uptakes in any of the four brain regions were regarded as amyloid β positivity [25] .
MRI acquisition
All participants underwent brain MRI including threedimensional (3D) T1 images at Samsung Medical Center using a 3.0 T MRI scanner (Philips 3.0 T Achieva; Best, the Netherlands). The following parameters were used for the 3D T1 images: sagittal slice thickness, 1.0 mm, over contiguous slices with 50% overlap; TR of 9.9 ms; TE of 4.6 ms; flip angle of 8°; and matrix size of 240 × 240 pixels, reconstructed to 480 × 480 over a field of view of 240 mm.
Amyloid and tau PET imaging analyses
PET images were co-registered to individual's MRIs, which were normalized to a T1-weighted MRI template. Using these parameters, MRI co-registered PET images were spatially normalized to the MRI template. MRI images were also segmented into brain tissue types and white matter images were classified to different lobes using the ANIMAL + INSECT algorithm [26, 27] . The quantitative cortical regional values were measured by an automated volume of interest (VOI) analysis tool using the automated anatomical labeling atlas. SPM version 8 through Matlab 2014b (Mathworks, Natick, MA, USA) was used for this analysis. FreeSurfer software package version 5.1 (http://surfer.nmr.mgh.harvard.edu/) was used to delineate subcortical region of interest (ROI) masks.
To measure regional AV1451 and THK5351 uptakes, we used the standardized uptake value ratios (SUVR) by dividing mean activity in target VOI by mean activity in the cerebellar hemispheric gray matter. We selected 28 cortical VOIs based on AAL template: bilateral frontal (superior and middle frontal gyri, medial part of superior frontal gyrus, opercular part of inferior frontal gyrus, triangular part of inferior frontal gyrus, supplementary motor area, orbital part of superior, middle, and inferior orbital frontal gyri, rectus and olfactory cortex), posterior cingulate gyri, parietal (superior and inferior parietal, supramarginal and angular gyri, and precuneus), lateral temporal (superior, middle and inferior temporal gyri, and heschl gyri), and occipital (superior, middle, and inferior occipital gyri, cuneus, calcarine fissure, and lingual and fusiform gyri). White matter images were parcellated into 2 regions: left hemisphere, and right hemisphere. White matter outline was set to 5 mm inside into white matter from the original outline to avoid gray matter spillover. Off-target VOIs were created by combining FreeSurfer ROIs: bilateral midbrain, thalamus, and basal ganglia.
Statistical analysis
Pearson correlation was performed to assess correlation between AV-1451 and THK-5351 in VOIs.
Results
Demographics
Demographic and clinical characteristics of our participants are shown in Table 1 . Our participants were divided into two groups of equal numbers in each disease group according to the order of PET scans. That is, one group (1 AD, 2 FTD, 1 NC) performed THK5351 PET followed by AV-1451 PET while the other group (1 AD, 2 FTD, 1 NC) underwent AV-1451 PET at first, then THK5351 PET were done. There were NC normal control no differences in mean interval time between two images (3.8 ± 1.5 and 4.2 ± 1.4 months, p = 0.733). AD cases (case 1 and case 2) were amyloid PET positive while NC and FTD cases were amyloid PET negative.
Visual inspection of AV-1451 and THK5351 bindings
On visual inspection, AD cases (cases 1 and 2) showed extensive cortical AV-1451 and THK5351 binding. However, AV-1451 binding appeared to be more prominent over the large regions of cortex, whereas medial temporal binding was higher with THK5351. In svPPA (case 3), THK5351 PET showed increased uptake in the anterior and inferior temporal regions while AV-1451 PET showed increased uptakes just in the white matter of those regions (Fig. 1) . In nfvPPA (case 4), the increased uptake was mainly observed in the left frontal white matter for both THK5351 and AV-1451 PET. However, uptake with THK5351 seemed to be more prominent than with AV-1451 (Fig. 1) . Two bvFTD patients (cases 5 and 6) showed increased THK5351 binding primarily in the right frontal and temporal regions, while increased AV-1451 bindings were observed just in the white matter of those regions (Fig. 1) . Two NC showed increased THK5351 binding in the medial temporal regions while there were no regions showing increased AV-1451 (Fig. 1) . THK5351 binding seemed to be more prominent in the white matter, basal ganglia, thalamus and midbrain than AV-1451 binding in all patients. SUVR in each area of all patients were arranged in supplementary data 1. Correlation between AV-1451 and THK5351 uptakes AV-1451 and THK5351 uptake was highly correlated in AD (r = 0.63, p = 0.009) and FTD (r = 0.69, p < 0.001) cases. Cortical AV1451 SUVR were higher than THK5351 SUVR in AD, whereas the opposite pattern was seen in FTD and controls (Fig. 2) . AD and FTD cases also showed high correlation (|r| = 0.61 to 0.99) between AV-1451 and THK5351 uptake in the white matter, midbrain, thalamus, and basal ganglia, with the exception of basal ganglia in AD cases (Fig. 3) . In AD and FTD cases, THK5351 uptake was more prominent in the white matter, midbrain, thalamus, and basal ganglia with wider variations. However, AD cases showed that THK5351 and AV-1451 uptake had similar variation in the white matter while FTD cases showed THK5351 uptake had wider variation in the white matter than AV-1451 uptake.
Discussion
In this study, we performed head to head comparisons of THK5351 and AV-1451 PET in patients clinically diagnosed with AD and FTD. We found that although THK5351 and AV-1451 tracers were highly correlated, cortical uptake of AV-1451 was more striking in AD cases, while cortical uptake of THK5351 was more prominent in FTD and NC cases. Both THK5351 and AV-1451, regardless of type of dementia, showed off-target binding in the white matter, midbrain, thalamus, and basal ganglia, but THK5351 Boff-target^binding was higher. Our preliminary results, therefore, suggest that AV-1451 is more sensitive and specific to AD type tau and less likely to present off-target binding, while THK5351 may mirror non-specific neurodegeneration.
Our first major finding was that AD cases showed higher cortical uptake of AV-1451 than THK5351. However, FTD cases showed higher cortical uptake of THK5351 than AV-1451. A previous study revealed that AV-1451 binding correlated with disease progression in the AD continuum [13] and also reflects Braak NFT staging [11] . However, other in vivo studies reported that AV-1451 binding seemed to be lower in FTD than in AD [13, 28] . Indeed, autoradiographic studies showed that AV-1451 had relatively selective binding to PHF-tau, the main form of aggregated tau in AD, than straight filaments of tau observed in Pick's disease, CBD, or PSP [17, 29, 30] . Our findings therefore suggest that AV-1451 might have higher affinity to AD type NFT than other forms of tau, compared to THK5351. Interestingly, other groups have reported elevated AV1451 uptake in FTD patients with specific mutations in the MAPT gene that yield BAD-like^PHF-tau Fig. 2 Correlation between THK5351 and AV-1451 uptake in cortical regions. AV-1451 and THK5351 uptake is highly correlated in AD and FTD cases. Cortical AV1451 SUVR are higher than THK5351 SUVR, whereas the opposite pattern is seen in FTD and controls. AD: Alzheimer's dementia; FTD: frontotemporal dementia aggregates that include a mix of 3R/4R isoforms, supporting the notion that this tracer shows a high-affinity for this specific type of tau aggregate [31, 32] .
Previously, THK5351 binding in AD was reported primarily in temporoparietal, but not frontal regions, even in advanced AD dementia cases, compared to cognitively normal elderly [8, 14] . Patients with various FTD syndromes such as nfvPPA, svPPA, and bvFTD have been reported to show increased THK5351 uptake [33] [34] [35] . Consistent with previous reports, our findings, therefore, suggest that THK5351 is more suitable for non-AD tauopathies compared to AV1451. Indeed, FTD syndrome showed that the topography of increased uptakes of THK5351 generally overlaps with brain atrophy on MRI and shows good correlation with clinical phenotypes while AV1451 showed increased uptakes just in white matter of atrophied regions on MRI (Table 2) . Alternatively, THK5351 binding may target a non-specific process related to neurodegeneration that co-localizes with tau pathology. FTD syndromes consist heterogeneous patients with a variety of underlying neuropathologies. Furthermore, Fig. 3 Correlations between THK5351 and AV-1451 uptakes in (A) white matter, (B) midbrain, (C) thalamus, and (D) basal ganglia. AD and FTD cases show high correlation between AV-1451 and THK5351 uptake in the white matter, basal ganglia, thalamus and midbrain with the exception of white matter and basal ganglia in AD cases. THK5351 SUVR in these regions are higher than AV-1451 SUVR. AD: Alzheimer's dementia; FTD: frontotemporal dementia ~80% patients with clinical svPPA are found to have FTLD-TDP rather than tau aggregates at autopsy [36, 37] , but a previous study of THK5351 showed that six of six svPPA cases had increased uptakes in the anterior and inferior temporal regions [34] . Indeed, a more recent study suggested that THK5351 may indicate nonspecific neuronal injury rather than specific tauopathy [35] . A previous report also showed that CJD patients had increased THK5351 uptake in cortical regions that also showed restricted diffusion on MRI [38] . Therefore, it might be related to MAO-B cross-reactivity. That is, THK-5351 might bind to increased MAO-B from reactive astrocytes in CJD [18, 39] . NC cases showed slight THK5351 uptakes in the cortical regions. Our findings were consistent with previous studies showing that normal elderly FTD frontotemporal dementia, PPA primary progressive aphasia had increased THK5351 uptakes in the cortical region. Considering that AV1451 showed increased uptake only in the choroid plexus, increased THK5351 uptakes in the cortical region might reflect MAO-B cross-reactivity [18] . In fact, in the post-selegiline scans, there was a significant uptake reduction in the cortical regions as well as striatum [19, 40] . However, one recent report revealed five svPPA patients showing increased AV-1451 uptake in the anterior temporal region [41] . In fact, when we lowered the cut-off value to SUVR 1.0, our svPPA patient also showed increased AV-1451 uptake in the anterior temporal region (supplementary data 2). It might be related to MAO-A cross-reactivity [42] . However, in the same scale (> SUVR 1.5) with THK5351, increased uptakes seemed to be more prominent in THK5351 than in AV-1451. Our second major finding was that off-target regions such as the white matter, midbrain, thalamus, and basal ganglia showed more prominent uptake of THK5351than was seen with AV-1451 with wider variation of uptake of THK5351 regardless of dementia types. Furthermore, even in NC, THK5351 binding seemed to be more prominent in these regions compared to AV-1451 binding. Therefore, our findings led us to postulate that different off-target patterns between THK5351 and AV-1451 binding might represent their binding affinities to different biomolecules. For example, increased THK5351 uptake in the basal ganglia and substantia nigra might reflect its binding to MAO-B [19] . Actually, even in normal controls, MAO-B expression increased in these regions [43] . Alternatively, increased AV-1451 uptake in these regions might reflect its binding to iron [30] . These regions are known to accumulate iron [44, 45] . In fact, a pathological study showed that AV-1451 might be associated with iron in these regions [30] . Also, it may be related to MAO-A. One previous study revealed that MAO-A inhibitor displaced the uptakes of AV1451 in normal brain tissue [42] . In conclusion, collectively, our findings suggested that AV-1451 is more sensitive and specific to Alzheimer disease type tau and shows lower off-target binding while THK5351 may reflect nonspecific neurodegeneration.
The strength of our study is that we performed a head to head comparison of two tau tracers in the same subjects, allowing us to directly compare the characteristics of the two tracers in a variety of conditions. However, there are several limitations. First, we did not have pathological findings in these cases. Further studies with autopsy will be needed to confirm our findings. Second, there were an average of four months interval between AV-1451 and THK5351 scans. The prolonged delay in some cases leaves open the possibility that significant tau burden increased after the first scan and prior to the second scan. This argument is mitigated to some degree by no deviation of order to one ligand in the same syndromes. Finally, our number of cases is small, and are findings need to be replicated in larger samples. It is important to evaluate more patients with pathologically or genetically confirmed or with syndromes which clinical diagnosis such as svPPA, PSP, FTD-ALS might be highly suggestive of pathologic diagnosis in the future study. Role of the funder The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
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